Field Reimbursement Managers (FRMs) for healthcare providers and office staff Patient Access Liaisons (PALs) for patients and their caregivers ForgingBridges Specialists for personalized coverage support and financial assistance options
Any coverage. We gather info, check eligibility, and start the process.
Learn More
Eligible patients may get Attruby free if uninsured, underinsured, coverage.
Learn More
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and
upper abdominal pain (5.5% vs 1.4%) were reported in
patients treated with Attruby versus placebo,
respectively. The majority of these adverse reactions
were mild and resolved without drug discontinuation.
Discontinuation rates due to adverse events were
similar between patients treated with Attruby versus
placebo (9.3% and 8.5%, respectively).
Laboratory Tests
increase in serum creatinine of 0.2 and 0.0 mg/dL and
a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2
was observed in the adults with ATTR-CM treated with
Attruby versus placebo, respectively, at Day 28 and
then stabilized. These changes were reversible after
treatment discontinuation.
Use in Specific
Populations Pregnancy & Lactation:
There are no
data on the use of Attruby in pregnant women. Animal
data have not shown developmental risk associated with
the use of Attruby in pregnancy. There are no
available data on the presence of Attruby in either
human or animal milk or the effects of the drug on the
breastfed infant or maternal milk production.
For product-related questions, resources, or starting people on treatment, Attruby representatives are here to help you and your office staff
Let's Connect
